Phase 3 Readout~month

Phase 3 Topline: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Ad

Indication
Neurodegenerative Diseases; Nervous System Diseases; Alzheimer's Disease

Other upcoming events for LLY

Phase 3 ReadoutPhase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharm
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placeb
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluatin
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compare
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retat

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Ad — LLY Phase 3 Readout | BioSniper